138 related articles for article (PubMed ID: 23358383)
1. Cost comparisons and methodological heterogeneity in cost-of-illness studies: the example of colorectal cancer.
Ó Céilleachair AJ; Hanly P; Skally M; O'Neill C; Fitzpatrick P; Kapur K; Staines A; Sharp L
Med Care; 2013 Apr; 51(4):339-50. PubMed ID: 23358383
[TBL] [Abstract][Full Text] [Related]
2. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
[TBL] [Abstract][Full Text] [Related]
3. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
Tscheulin DK; Drevs F
Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
[TBL] [Abstract][Full Text] [Related]
4. Costs and cost-effectiveness of colorectal cancer prevention and therapy.
Schrag D; Weeks J
Semin Oncol; 1999 Oct; 26(5):561-8. PubMed ID: 10528905
[TBL] [Abstract][Full Text] [Related]
5. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study.
Etzioni R; Ramsey SD; Berry K; Brown M
Health Econ; 2001 Apr; 10(3):245-56. PubMed ID: 11288190
[TBL] [Abstract][Full Text] [Related]
6. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
7. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data.
Lang K; Lines LM; Lee DW; Korn JR; Earle CC; Menzin J
Clin Gastroenterol Hepatol; 2009 Feb; 7(2):198-204. PubMed ID: 18849013
[TBL] [Abstract][Full Text] [Related]
8. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
[TBL] [Abstract][Full Text] [Related]
9. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer.
Ramsey SD; Berry K; Etzioni R
Am J Gastroenterol; 2002 Feb; 97(2):440-5. PubMed ID: 11866285
[TBL] [Abstract][Full Text] [Related]
10. Patient navigation for breast and colorectal cancer in 3 community hospital settings: an economic evaluation.
Donaldson EA; Holtgrave DR; Duffin RA; Feltner F; Funderburk W; Freeman HP
Cancer; 2012 Oct; 118(19):4851-9. PubMed ID: 22392629
[TBL] [Abstract][Full Text] [Related]
11. Economic studies in colorectal cancer: challenges in measuring and comparing costs.
Yabroff KR; Borowski L; Lipscomb J
J Natl Cancer Inst Monogr; 2013; 2013(46):62-78. PubMed ID: 23962510
[TBL] [Abstract][Full Text] [Related]
12. Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source?
Yabroff KR; Warren JL; Banthin J; Schrag D; Mariotto A; Lawrence W; Meekins A; Topor M; Brown ML
Med Care; 2009 Jul; 47(7 Suppl 1):S64-9. PubMed ID: 19536016
[TBL] [Abstract][Full Text] [Related]
13. Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.
Dahham J; Rizk R; Kremer I; Evers SMAA; Hiligsmann M
Pharmacoeconomics; 2021 Jul; 39(7):789-807. PubMed ID: 33956330
[TBL] [Abstract][Full Text] [Related]
14. Methodological considerations in the assessment of direct and indirect costs of back pain: A systematic scoping review.
Zemedikun DT; Kigozi J; Wynne-Jones G; Guariglia A; Roberts T
PLoS One; 2021; 16(5):e0251406. PubMed ID: 33974661
[TBL] [Abstract][Full Text] [Related]
15. Direct medical cost associated with colorectal cancer in north of Jordan.
Alefan Q; Malhees R; Mhaidat N
Curr Probl Cancer; 2017; 41(5):371-381. PubMed ID: 28629637
[TBL] [Abstract][Full Text] [Related]
16. Cost-of-Illness in Rare Diseases.
Linertová R; García-Pérez L; Gorostiza I
Adv Exp Med Biol; 2017; 1031():283-297. PubMed ID: 29214579
[TBL] [Abstract][Full Text] [Related]
17. Analyzing the variation in treatment costs for colorectal cancer (CRC): A retrospective study to assess an underlying threat among the Vietnamese.
Le NQ; Vo TQ; Doan TD
J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S34-S40. PubMed ID: 31369532
[TBL] [Abstract][Full Text] [Related]
18. The Direct and Indirect Costs of Colorectal Cancer in Vietnam: An Economic Analysis from a Social Perspective.
Tran BT; Choi KS; Nguyen TX; Sohn DK; Kim SY; Suh JK; Phan VS; Pham HT; Nguyen MH; Nguyen TB; Hoang HK; Nguyen TTB; Nguyen MT; Oh JK
Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375113
[TBL] [Abstract][Full Text] [Related]
19. An integrative cross-design synthesis approach to estimate the cost of illness: an applied case to the cost of depression in Catalonia.
Bendeck M; Serrano-Blanco A; García-Alonso C; Bonet P; Jordà E; Sabes-Figuera R; Salvador-Carulla L;
J Ment Health; 2013 Apr; 22(2):135-54. PubMed ID: 23323630
[TBL] [Abstract][Full Text] [Related]
20. Methodological considerations in cost of prostate cancer studies: a systematic review.
Molinier L; Bauvin E; Combescure C; Castelli C; Rebillard X; Soulié M; Daurès JP; Grosclaude P
Value Health; 2008; 11(5):878-85. PubMed ID: 18494749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
